Summary of Dr. Chapa’s OBGYN Clinical Pearls

Episode: Can Oral Probiotics Reduce Recurrent sPTB?

Release Date: March 5, 2026
Host: Dr. Chapa

Main Theme

This episode explores whether oral probiotics can reduce the risk of recurrent spontaneous preterm birth (sPTB), particularly in women with a prior history of preterm birth. Dr. Chapa reviews recent evidence, focusing on a brand-new prospective trial from Japan, and contextualizes this with prior research, practical considerations, and ongoing debates in perinatology.

Key Discussion Points & Insights

The Popularity and Hype around Probiotics

• General popularity: Probiotics are widely marketed as essential for "gut health" and immunity (01:18).
• Medical reality: The gut does play a significant role in immunity; about 70% of the immune system originates in the GI tract. There's established, though nuanced, linkage between gut health and inflammatory or even some mental health outcomes (01:18–02:50).
• Clinical question: While probiotics are popular, especially among young women in university town settings, they are not universally recommended in prenatal care—but patients often ask about their use in pregnancy (02:51–04:50).

Probiotics in Obstetrics – The Evidence So Far

• Effect on pregnancy: Historical data and clinical guidelines do not generally recommend probiotics as a universal supplement in pregnancy, especially for preterm birth prevention (04:50).
• Safety: No substantive evidence that oral or prebiotic (fiber-based) supplements cause harm in pregnancy, with exception of a possible (but debated) connection to increased preeclampsia risk based on timing and formulation (05:10–06:25).

Review of Existing Studies

• Probiotics in BV & Vaginal Health: Past episodes have covered how vaginal (vs. oral) probiotics, particularly specific lactobacilli strains, may benefit women with bacterial vaginosis (BV) and possibly influence obstetric outcomes (09:34–11:30).
• Type, Timing, and Route Matter: The type of probiotic (strain, colony count, and form—refrigerated/live vs. freeze-dried), the timing in pregnancy, and the administration route (oral vs. vaginal) all heavily influence clinical effects and study results (12:30–14:10).
• Population heterogeneity: Most existing studies mix high- and low-risk populations and probiotic strains, making firm conclusions difficult.
• Large Cohort Data (Norway Study, BMJ Open 2018):
  • Early probiotic milk in pregnancy: May reduce preterm birth risk (OR 0.79, CI 0.6–0.97).
  • Late intake: Associated with reduced risk of preeclampsia.
  • These were not RCTs, so methodology limits the findings (15:12–17:00).
• Meta-analyses and Reviews:
  • Systematic reviews (Cochrane 2021) and umbrella meta-analyses are conflicting: Some signal a possible increase in preeclampsia risk (RR 1.85 to 1.23) but no major adverse effects otherwise (17:00–20:30).
  • Effect on preterm birth recurrence: So far, no strong RCT evidence that oral or vaginal probiotics significantly reduce recurrent preterm birth (21:20).

Notable Quotes

• "70% of all of our immune system and the origin of its function is in the GI tract. Guys, we don't have to debate the fact that there's a link between gut health and overall health, overall inflammation, even some mental health... there’s definitely some association." – Dr. Chapa (01:18)
• "No study has shown that [prebiotics] lead to some kind of bacterial sepsis or actual harm in pregnancy." – Dr. Chapa (06:10)
• "You can't just do a study, say, and call it probiotics because there’s different strains, there’s different colony counts... when we try to link all studies under one umbrella of probiotics, there’s just way too much there to try to figure out." – Dr. Chapa (13:20)
• "[The Japanese study] was single-arm, non-blinded. Thankfully, it was prospective... So it's got some limitations, right, in its design... what were they trying to do?" – Dr. Chapa (04:50)

Deep Dive: The New Japanese Study (Gray Journal, Feb 2026)

Segment starts: 24:19

Design & Methods

• Type: Prospective, single-arm, multi-center trial (not randomized; no control group).
• Population: Pregnant women aged 18–43 with prior spontaneous PTB at 31 sites in Japan.
• Intervention: Oral probiotics, chiefly Clostridium butyricum (with some other strains), starting as early as 10–14 weeks gestation through 36 weeks, 6 days.
• Primary endpoint: Recurrent sPTB under 37 weeks vs. historical Japanese national rate (22.3%).

Key Findings

• Results:
  • Recurrent sPTB <37 weeks: 14.9% (vs. 22.3% historical, improvement of ~7.4% absolute).
  • sPTB <34 weeks: 3.5%.
  • Extreme sPTB (<28 weeks, among those with previous extreme PTB): 1.5%.
  • Safety: No stillbirths, serious adverse events, or major side effects reported.

Clinical Interpretation & Limitations

• The improved rates are striking, but the design lacks randomization, blinding, and a contemporary control group—the main caution for interpreting causality.

• Authors and Dr. Chapa underscore need for well-designed RCTs before considering practice change.

• The choice of Clostridium butyricum as a "good guy" in the clostridia family is clarified—this is not the dangerous C. diff or C. tetani.

  • "Clostridium species are varied and they are a big part of normal gastrointestinal flora... Some are actually very helpful." – Dr. Chapa (22:00)

• "In this non-controlled, single-arm, non-blinded study, oral probiotics with Clostridium specific strain... actually had wonderful reduction, not just in overall preterm birth, but extreme early preterm birth under 28 weeks. Are we ready for this to be mainstream? No. ... But if a patient asks ... you go, 'Well, we know no one gets sepsis. We know it can possibly help...’" – Dr. Chapa (28:00)

Other Clinical Pearls

• Neonatal Probiotics: There's good NICU evidence that certain probiotic strains in neonates (esp. preemies) reduce morbidities like necrotizing enterocolitis (NEC). This does not directly translate to prenatal maternal use (11:50–12:30).
• Timing in Pregnancy:
  • Earlier probiotic use may help reduce sPTB.
  • Later probiotic use possibly reduces preeclampsia risk, though data is mixed and based on non-RCTs.
• Progesterone context: With declining evidence for 17-OH progesterone for preventing preterm birth, interest has shifted to alternatives like probiotics (31:00).
• Safety Recap: Probiotics are generally safe in pregnancy (barring rare allergies or poor-quality over-the-counter supplements). Data about preeclampsia risk remains gray.
• Counseling tip: This new Japanese study suggests oral probiotics could be beneficial. Patients should be counseled with data—not just opinion—and advised of limits of current evidence.

Notable Quotes & Memorable Moments

• "If somebody asks... during pregnancy, you need to be armed with the data for that, especially if they have a high risk factor like previous preterm birth." – Dr. Chapa (02:51)
• "No one gets sepsis... not sure if it helps with preterm birth, but maybe. Depends on which strain you take. The risk of preeclampsia is gray. But maybe if you take it later... then maybe it can help." – Dr. Chapa (30:15)
• "[With this new study,] it was kind of impressive... Among 343 enrolled patients... the recurrence rate... under 37 weeks was 14.9%. Remember, the baseline was supposed to be 22. So this was 14.9%... an obvious improvement." – Dr. Chapa (25:30)
• "Progesterone kind of went out the window... So in 2026, this is where we're at. We're looking at probiotics for preterm birth because nothing else has really done what it's supposed to do." – Dr. Chapa (31:10)

Timestamps of Key Segments

• Probiotic hype & basics: 00:36–05:00
• Probiotics and women’s health (BV, vaginal vs. oral): 09:34–13:20
• Large population cohort studies (Norway, BMJ 2018): 15:12–17:00
• Systematic reviews and meta-analyses (Cochrane 2021, umbrella meta-analysis 2025): 17:00–21:20
• Context: Lack of prior strong evidence for recurrence prevention: 21:20–24:19
• Deep dive: The new Japanese single-arm probiotic trial: 24:19–30:15
• Clinical counseling and summary of what to tell patients: 30:15–31:10
• Progesterone context, closing remarks: 31:10–32:00

Take-Home Clinical Pearls

• Evidence for oral probiotics reducing recurrent sPTB is intriguing but limited by trial design.
• Effectiveness may depend on strain, dose, timing, and specific patient context.
• Safety profile is generally good, with possible minor increased risk for preeclampsia based on some analyses.
• Counsel patients with up-to-date data and the caveats: probiotics are not recommended as a routine for sPTB prevention, but ongoing research is promising, especially as previous mainstream interventions (like 17-OH progesterone) lose ground.
• Stay tuned for higher-quality RCTs before changing standard practice.

For more in-depth breakdowns, revisit Dr. Chapa’s Clinical Pearls archive, especially on BV, progesterone, and preterm birth prevention. Medical education isn’t boring here!